Ср | 6 / Ц Appl. Ser. No.: 10/616,139 / Ц

THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Serial No.:

10/616,139

Filing Date:

07/09/2003

Applicant(s):

Gary R. Epler

Title:

DIRECTED MEDICATION SYSTEM AND METHOD

Art Unit:

1614

Examiner:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Non-Fee Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In compliance with the provisions of 37 C.F.R. §1.56 and 37 C.F.R. §\$1.97-1.99, the Applicant is hereby making of record the enclosed PCT International Search Report and copies of cited references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

- [] (1) The enclosed Information Disclosure Statement is being filed within three months of the filing date or within three months of the entry of the national stage of the above identified application. Accordingly, applicant(s) believe that no fee or certification is required.
- [] (2) Applicant(s) believe the enclosed Information Disclosure Statement is entitled to the benefit of 37 CFR ~1.97(b)(3). Accordingly, applicant(s) believe that no fee or certification is required.

PETITION UNDER 37 CFR §1.97(d)

[] (2) Pursuant to 37 CFR §1.97(d), applicant(s) hereby petition the Commissioner to consider the attached Information Disclosure Statement. Applicant(s) state that the

Appl. Ser. No.: 10/616,139

issue fee has not been paid and that a certification under 37 CFR §1.97(e) is provided herein, along with the petition fee of \$130.00 required under 37 CFR §1.17(i)(1).

CERTIFICATION UNDER 37 CFR §1.97(e)(1)

[X] (3) The undersigned hereby certifies that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of this statement.

CERTIFICATION UNDER 37 CFR §1.97(e)(2)

- [] (4) The undersigned hereby certifies that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual having a duty of disclosure as set forth in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- [] (5) The information disclosure fee of \$200.00 required by 37 CFR §I.17(p) is believed to be due and is enclosed herewith.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy Rule 98(a)(3) even if in a foreign language, since the few terms of relevance therein are deemed of

Appl. Ser. No.: 10/616,139

universal cognizance. However, applicant does not necessarily adopt the position reflected by that report.

Respectfully submitted,

Date: // // ෭ / º 9 Robert R. Deleault, Esq.

Reg. No. 39,165

Attorney for the Applicants

Kolme as Ince

41 Brook Street

Manchester, NH 03104 Tel. (603) 668-1971

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on November 12, 2004:

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/616,139 Filing Date 07/09/2003 INFORMATION DISCLOSURE First Named Inventor Gary R. Epler STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number epler0703 Sheet

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (# known)}			Figures Appear	
		US-	1			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		•		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FOREIG	N PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	1	EP 0 741 296 A1	11-06-1996	Institut Jacque		
	2	EP 0 269 362 A2	06-01-1988	SmithKline Diag		
	3	EP 0 717 283 A2	06-19-1996	Ortho Pharmaceu		
	4	WO 00/61802	10-19-2000	Lingard Label C		
	5	WO 95/33996	12-14-1995	Selfcare Inc.		

Examiner		Date	
Signature		Considered	
		,	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for form 1449/PTO			Complete if Known		
Constitut	O IOI IOIIII 1440II 10			Application Number	10/616,139	
INFO	ORMATION	DIS	CLOSURE	Filing Date	07-09-2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Gary R. Epler	
	(Use as many she	oto ao n	neoccand.	Art Unit	1614	
	Ose as many sne	rets as in	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	epler0703	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	6	GERD SCHMIDT, Pharmacogenomics: implications for laboratory medicine, Clinica Chimica Acta, 43-53, 2001, 308, Elsevier Science B.V.	
	7	D-FWMALL.COM, Home Based DNA Test Kit Press Release 3/24/99, pages 1-2.	

Examiner	Date	***************************************
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.